Superiority of Ablation Therapy Using HALO System Demonstrated for
Eradicating Barrett's Esophagus and Reducing Risk for Disease Progression

SAN DIEGO, May 19 /PRNewswire/ -- Booth #2349 -- Digestive Disease Week
-- BARRX Medical, Inc., a technology leader in the design and manufacture
of medical devices for digestive diseases, today announced the presentation
of a landmark study entitled, "A Randomized, Multicenter, Sham-Controlled
Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's
Esophagus (BE) Containing Dysplasia: Interim Results of the AIM Dysplasia
Trial." The study was presented by Nicholas J. Shaheen, M.D., Associate
Professor of Medicine and Epidemiology, The University of North Carolina,
during the clinical plenary session of the American Gastroenterological
Association at the Digestive Disease Week meeting in San Diego, California.

"This is a very well-designed trial conducted in a rigorous manner at
19 expert U.S. centers, each having experience in the management of
Barrett's esophagus and dysplasia," said Dr. Shaheen. "Our interim results
are highly promising, demonstrating superiority for ablation therapy for
eliminating Barrett's and dysplasia, as well as reducing the risk for
disease progression. Although we continue to complete the trial, these
results may ultimately change the paradigm for how gastroenterologists
manage their patients with Barrett's esophagus."

Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients with a
diagnosis of dysplastic Barrett's esophagus, the most advanced stage of
this precancerous condition. As a result of injury from gastroesophageal
reflux disease or GERD, the normal esophageal lining is replaced with
abnormal cells (Barrett's tissue), predisposing the patient to a higher
risk for developing cancer of the esophagus. Patients with Barrett's who
develop cancer, typically do so through a series of steps, starting with
Barrett's, then Barrett's with low-grade dysplasia (minor pre-cancerous
changes) or high-grade dysplasia (severe pre-cancerous changes), and then
finally cancer. The present study included patients with Barrett's
containing low- or high-grade dysplasia.

Patients in the study were randomly assigned to receive either
endoscopic ablation therapy using the HALO ablation system (BARRX Medical,
Inc.), or, a sham (placebo) intervention. Tissue samples, or biopsies, were
subsequently taken at regular intervals over the next year to assess for
Barrett's, dysplasia, and / or cancer. Comparative pathology results at one
year served as the primary outcome for the trial. The study endpoints were
the disappearance of dysplasia, as well as the more rigorous endpoint of
complete eradication of all Barrett's tissue. In the latter case, the
esophageal lining is deemed normal, with no sign of residual abnormal
cells.

At one year follow-up, the treatment group had a much higher complete
eradication rate for both dysplasia and Barrett's cells as compared to the
untreated sham group, with statistical significance. In fact, more than
three quarters of the treated patients had no detectable Barrett's at the
end of the treatment period, compared to sham patients (all of whom still
had Barrett's.) Further, the progression rate to higher grades of dysplasia
and esophageal cancer was significantly lower in the treatment group as
compared to the sham group.

About BARRX Medical and the HALO Ablation Technology

BARRX Medical, Inc. develops treatment solutions for Barrett's
esophagus, a precancerous condition of the lining of the esophagus
(swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its
flagship product, the HALO360 System, provides uniform and controlled
therapy at a consistent depth, which can remove Barrett's esophagus and
allow the re-growth of normal cells. In the largest clinical trial
conducted and published to date (the AIM Trial), 98.4 percent of patients
were Barrett's-free after two and a half years. The system used in the
clinical trials was cleared by the U.S. Food and Drug Administration in
2001 and has been commercially available since January 2005. The HALO90
System the company's second ablation product, which is mounted on the end
of an endoscope and used to treat smaller, non-circumferential areas of
disease, was introduced in 2007. More than 14,000 procedures have been
performed in over 200 hospitals around the world. Based in Sunnyvale,
Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held.
Additional information about BARRX Medical, Inc. and the HALO ablation
system of products is available at http://www.barrx.com.

About Digestive Disease Week

Digestive Disease Week (DDW) is the largest international gathering of
physicians, researchers, and academicians in the fields of
gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
Jointly sponsored by the American Association for the Study of Liver
Diseases (AASLD), the American Gastroenterological Association (AGA), the
American Society for Gastrointestinal Endoscopy (ASGE), and the Society for
Surgery of the Alimentary Tract (SSAT), DDW takes place May 17-22, 2008 in
San Diego, CA. The meeting showcases approximately 5,000 abstracts and
hundreds of lectures on the latest advances in GI research and technology.

(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...

(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings. The ...

(Date:11/28/2016)... , Nov. 28, 2016 ... a rate of 16.79%" The biometric system market ... grow further in the near future. The biometric system ... billion in 2022, at a CAGR of 16.79% between ... system, integration of biometric technology in smartphones, rising use ...

(Date:11/21/2016)... Nov. 21, 2016 Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...